Analysis of protease inhibitor combinations in vitro: activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates.
D002219:Carbamates; D024882:Drug Resistance, Viral; D004797:Enzyme-Linked Immunosorbent Assay; D005663:Furans; D005838:Genotype; D015658:HIV Infections / Q000821:virology; D017320:HIV Protease Inhibitors / Q000494:pharmacology*; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D061466:Lopinavir; D011725:Pyridines / Q000494:pharmacology*; D011744:Pyrimidinones / Q000494:pharmacology*; D011753:Pyrones / Q000494:pharmacology*; D012367:RNA, Viral / Q000096:biosynthesis / Q000235:genetics; D013449:Sulfonamides / Q000494:pharmacology*
D002219:Carbamates; D005663:Furans; D017320:HIV Protease Inhibitors; D011725:Pyridines; D011744:Pyrimidinones; D011753:Pyrones; D012367:RNA, Viral; D013449:Sulfonamides; D061466:Lopinavir; C095108:amprenavir; C107201:tipranavir